Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 60
- Profitability 100
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 78/100 — Elite Quality
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Alnylam Pharmaceuticals, Inc. (ALNY) is a Biotechnology company in the Healthcare sector. Compound Radar rates Alnylam Pharmaceuticals, Inc. 78/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 45.23
- Forward P/E 20.66
- PEG 0.34
- EV/Revenue 7.35
Profitability
- Revenue Growth 66.9%
- Gross Margin 79.7%
- Operating Margin 17.9%
- Net Margin 16.1%
- ROE 96.6%
Financial strength
- Cash $3.31B
- Debt $2.99B
- Net Cash $320.66M
- Free Cash Flow $465.38M
- Current Ratio 3.06
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- ACADIA Pharmaceuticals Inc. Biotechnology ACAD$27.58 75 Health 75 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BioMarin Pharmaceutical Inc. Biotechnology BMRN$64.63 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Alnylam Pharmaceuticals, Inc. (ALNY).